Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

A Pilot Study of Randomized, Head-to-Head of Metformin Versus Topiramate in Obese People With Schizophrenia

Peng, Po-Jui MD; Ho, Pei-Shen MD; Tsai, Chia-Kuang MD; Huang, San-Yuan MD, PhD; Liang, Chih-Sung MD

doi: 10.1097/WNF.0000000000000188
Original Articles
Buy

Objectives A number of research studies support the weight loss effects of metformin and topiramate for obese people with schizophrenia. However, only a few studies have addressed the sustainability of the body weight reduction after discontinuation of these drugs. Moreover, head-to-head studies are still lacking. The study aims to evaluate and compare the efficacy of metformin and topiramate in weight reduction and weight maintenance after discontinuation of these drugs in obese people with schizophrenia.

Methods Twenty-two obese inpatients with schizophrenia were recruited and randomized into the metformin group (n = 11; daily dose, 1000 mg) and the topiramate group (n = 11; daily dose, 100 mg). A head-to-head, fixed-dose, and single-blinded design was used. Ten obese patients with schizophrenia of similar sex as that of the treated group were included as the control group.

Results After a 4-month treatment, the metformin group showed a body weight reduction of 3.8 kg, and the topiramate group showed a reduction of 2.7 kg. However, the reduction could be sustained only in the metformin group at 3 and 9 months after metformin discontinuation. Interestingly, 3 months after treatment discontinuation, leptin levels showed a reduction in both metformin (baseline, 25.3 ± 14.7, week 7: 5.7 ± 3.7 ng/mL) and topiramate (baseline: 28.4 ± 16.1, week 7: 9.2 ± 15.5 ng/mL) groups.

Conclusions The trend of weight changes supports the superiority of metformin at 1000 mg/d over topiramate at 100 mg/d in weight reduction and weight maintenance.

*Department of Psychiatry, Beitou Branch, Tri-Service General Hospital †Graduate Institute of Medical Sciences, ‡Departments of Neurology, and §Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC.

Address correspondence and reprint requests to Chih-Sung Liang, MD, Beitou Branch, Tri-Service General Hospital, Taipei, Taiwan, ROC, No. 60, Xinmin Road, Beitou District, Taipei City 112, Taiwan, ROC; E-mail: lcsyfw@gmail.com

Conflict of interest: None.

Source of Funding: Funding for this study was provided by Civilian Administration Division of Beitou Branch, Tri-Service General Hospital (BT-100-03). The Civilian Administration Division had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.